Pancreatic Cancer Research

ResearcherTongji HospitalNo recent work listed

Xu Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2848-5102; OpenAlex author ID A5100342495. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 3 papers · 2019: none · 2020: none · 2021: none · 2022: 1 paper

Papers 9

  1. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  2. Loss of Linc01060 induces pancreatic cancer progression through vinculin-mediated focal adhesion turnover. Co-author DOI 10.1016/j.canlet.2018.06.015↗
  3. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. First author DOI 10.1038/s41598-018-22493-5↗
  4. Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.24443↗
  5. Par3 regulates invasion of pancreatic cancer cells via interaction with Tiam1. Co-author DOI 10.1007/s10238-015-0365-2↗
  6. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Co-author DOI 10.1080/15548627.2016.1191722↗
  7. The NOTCH ligand JAGGED2 promotes pancreatic cancer metastasis independent of NOTCH signaling activation. Co-author DOI 10.1158/1535-7163.mct-14-0501↗
  8. microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Co-author PMID 25550779↗
  9. Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16. Co-author DOI 10.1007/s11596-011-0481-5↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Renyi Qin · 6 shared papers, 2015–2022 · strength 0.47
  2. Min Wang · 7 shared papers, 2011–2022 · strength 0.47
  3. Xingjun Guo · 6 shared papers, 2016–2022 · strength 0.47
  4. Xiuhui Shi · 4 shared papers, 2018–2022 · strength 0.37
  5. Yan Zhao · 4 shared papers, 2016–2022 · strength 0.31
  6. Ruizhi He · 4 shared papers, 2016–2022 · strength 0.31
  7. Shutao Pan · 3 shared papers, 2018–2022 · strength 0.27
  8. Min Zhou · 2 shared papers, 2018–2022 · strength 0.19
  9. Chunle Zhao · 2 shared papers, 2018–2022 · strength 0.19
  10. Jianxin Jiang · 3 shared papers, 2014–2016 · strength 0.14
  11. Yuqing Zhang · 1 shared paper, 2022 · strength 0.12
  12. Min Li · 1 shared paper, 2022 · strength 0.12
  13. Yuhui Liu · 1 shared paper, 2022 · strength 0.12
  14. Taoyuan Yin · 1 shared paper, 2022 · strength 0.12
  15. Zhijun Zhou · 1 shared paper, 2022 · strength 0.12
  16. Jingxuan Yang · 1 shared paper, 2022 · strength 0.12
  17. Mingyang Liu · 1 shared paper, 2022 · strength 0.12
  18. Chengyi Sun · 2 shared papers, 2014–2016 · strength 0.09
  19. Chengjian Shi · 2 shared papers, 2016 · strength 0.09
  20. Shuo Yu · 1 shared paper, 2018 · strength 0.08
  21. Min Zhou · 1 shared paper, 2018 · strength 0.07
  22. Guoli Guo · 1 shared paper, 2015 · strength 0.05
  23. Yufeng Hu · 1 shared paper, 2015 · strength 0.05
  24. Hudan Liu · 1 shared paper, 2015 · strength 0.05
  25. Renyi Qin · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.